MedTrace Logo

An Observational Study of MabThera in Participants With Severe Active Rheumatoid Arthritis

NCT01613027 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 135

Last updated 2016-10-24

Study results available
· View outcomes & findings →

Summary

This observational study will evaluate the effect on disease activity and the safety in routine clinical practice of MabThera (rituximab) in participants with active seropositive rheumatoid arthritis, who have an inadequate response to one or more tumour necrosis factor inhibitor (anti-TNF) therapies.

Conditions

Interventions

BIOLOGICAL

Rituximab

Rituximab administered according to prescribing information and normal clinical practice.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • Greece

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01613027 on ClinicalTrials.gov